NYSEAMERICAN:CRMD - CorMedix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.86 +0.15 (+8.77 %) (As of 01/23/2019 09:27 AM ET)Previous Close$1.71Today's Range$1.57 - $1.9052-Week Range$0.17 - $2.40Volume3.51 million shsAverage Volume3.31 million shsMarket Capitalization$195.88 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey. Receive CRMD News and Ratings via Email Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:CRMD Previous SymbolNYSEMKT:CRMD CUSIPN/A Webwww.cormedix.com Phone+1-908-5179500Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees14 Outstanding Shares105,310,000Market Cap$195.88 million OptionableOptionable CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions What is CorMedix's stock symbol? CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD." How were CorMedix's earnings last quarter? CorMedix Inc. (NYSEAMERICAN:CRMD) announced its quarterly earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.05. The biotechnology company had revenue of $0.37 million for the quarter, compared to analysts' expectations of $0.05 million. View CorMedix's Earnings History. When is CorMedix's next earnings date? CorMedix is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for CorMedix. What price target have analysts set for CRMD? 2 brokerages have issued twelve-month target prices for CorMedix's stock. Their forecasts range from $3.50 to $6.00. On average, they expect CorMedix's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 155.4% from the stock's current price. View Analyst Price Targets for CorMedix. What is the consensus analysts' recommendation for CorMedix? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix. What are Wall Street analysts saying about CorMedix stock? Here are some recent quotes from research analysts about CorMedix stock: 1. HC Wainwright analysts commented, "We derive a value of $470M for Neutrolin using a 12% discount rate and 90% probability of success, along with a 23% effective tax rate, or a price per share of $3.50, taking into account $150M from additional value drivers (ex-U.S. sales, taurolidine gel formulation, and future medical device applications)—up from the prior $120M—and ~141M fully-diluted shares outstanding—including issuance of about 35M more shares due to warrant exercises and further stock issuances—as of end-2019. Our valuation of Neutrolin has risen to $350M from the previous $300M, based on higher peak sales potential." (1/18/2019) 2. According to Zacks Investment Research, "CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company's therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin®. CorMedix Inc. is based in Summit, New Jersey. " (12/14/2018) Has CorMedix been receiving favorable news coverage? Press coverage about CRMD stock has been trending very positive on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CorMedix earned a news sentiment score of 3.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. Are investors shorting CorMedix? CorMedix saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 13,846,044 shares, a decrease of 3.4% from the December 14th total of 14,328,775 shares. Based on an average trading volume of 1,727,019 shares, the short-interest ratio is currently 8.0 days. Currently, 13.8% of the shares of the company are short sold. View CorMedix's Current Options Chain. Who are some of CorMedix's key competitors? Some companies that are related to CorMedix include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Aerpio Pharmaceuticals (ARPO), Almirall (LBTSF), Altimmune (ALT) and Ampio Pharmaceuticals (AMPE). Who are CorMedix's key executives? CorMedix's management team includes the folowing people: Mr. Khoso Baluch, CEO & Director (Age 61)Mr. Robert W. Cook, Chief Financial Officer (Age 63)Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 75)Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 40)Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance Who are CorMedix's major shareholders? CorMedix's stock is owned by a number of of institutional and retail investors. Top institutional investors include Steward Partners Investment Advisory LLC (0.07%). Company insiders that own CorMedix stock include Antony Pfaffle, Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Institutional Ownership Trends for CorMedix. Which institutional investors are buying CorMedix stock? CRMD stock was purchased by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC. Company insiders that have bought CorMedix stock in the last two years include Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Insider Buying and Selling for CorMedix. How do I buy shares of CorMedix? Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CorMedix's stock price today? One share of CRMD stock can currently be purchased for approximately $1.86. How big of a company is CorMedix? CorMedix has a market capitalization of $195.88 million. CorMedix employs 14 workers across the globe. What is CorMedix's official website? The official website for CorMedix is http://www.cormedix.com. How can I contact CorMedix? CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500. MarketBeat Community Rating for CorMedix (NYSEAMERICAN CRMD)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 210 (Vote Outperform)Underperform Votes: 210 (Vote Underperform)Total Votes: 420MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?